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Letters to the Editor762LGE (4 but 6 SD) is a better predictor of ventricular tachyar-
hythmias than high signal intensity LGE (6 SD). In conclusion,
s Green et al. (1) appropriately point out, the more important
uestion is not whether LGE predicts SCD, but rather does it
dd incremental information above and beyond that provided by
he conventional and less expensive models based on clinical and
chocardiographic factors. Would we be able to identify patients
ith 2 or more conventional risk factors that would not need
CD based on CMR and would we be able to correctly predict
he need for ICD in a subset of patients with no conventional
isk factors?
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While we agree that sustained ventricular tachycardia (VT)/
ventricular fibrillation (VF) is an important arrhythmic endpoint,
and is certainly a marker for increased risk of sudden cardiac death
(SCD), our goal was specifically to evaluate hard endpoint of SCD
and aborted SCD. As 3 of 4 included studies did not uniformly
report on the incidence of sustained/nonsustained VT/VF, true
prevalence of these events could not be adequately assessed from
these studies. Furthermore, additional studies which do not assess
SCD have demonstrated an association between cardiac magnetic
resonance (CMR) and VT and would need to be included for an
adequate analysis. As proposed, a future multicenter study would
enable more uniform assessment of these arrhythmic events and
other endpoints in the context of traditional risk markers, genetics, and other CMR markers without the statistical limitations inherent
n the current limited data.
Given the assessment of heterogeneity, a fixed effects model was
tatistically justifiable; however, the point made by Alla et al.
egarding the assessment of heterogeneity with a small number of
tudies is well taken. The pooled raw data was reanalyzed assuming
random effects model with very similar results (Table 1). Only
ardiovascular death failed to reach statistical significance (p  0.1)
ith a random effects model. This discrepancy is likely driven by
he low numbers and the discordant results of the Maron study (1),
hich had a younger population as compared with the other 3
tudies (2–4).
Alla et al. raise an interesting point with regard to the current
ethods for quantifying left gadolinium enhancement (LGE) on
he basis of a fixed standard deviation of signal intensity relative to
he remote myocardium, which is dependent upon a number of
onfounding factors including the signal-to-noise ratio of the
mages, gadolinium dose, timing of imaging after contrast admin-
stration, noise statistics, and the assumption that the remote
yocardium is “normal,” which is now suspect given evidence for
iffusely abnormal T1 values (indicating diffuse fibrosis) even in the
bsence of focal fibrosis. This more diffuse fibrosis may also be a risk
or arrhythmic events. Further standardization in the definition of
bnormal LGE in hypertrophic cardiomyopathy would enable us to
etermine if cutoffs based upon SD are truly predictive.
The question about whether LGE adds incremental information
o conventional risk factors cannot be answered with the currently
vailable data. The studies performed to date possess an older
opulation of whom the vast majority have 2 traditional risk
actors for SCD (as their eligibility for CMR in these studies
ignified that they had not already received implantable
ardioverter-defibrillator [ICD] placement for primary prevention
s indicated for those with 2 traditional risk factors). Alla et al.
ropose 2 distinct clinical scenarios in which thoughtful clinical
valuation by the cardiologist is vital: no scar by CMR with 2
raditional risk factors versus scar by CMR with 2 traditional risk
actors. In the first scenario, one must acknowledge the risks
Table 1. Adverse Cardiovascular Events: Fixed Effect Versus
Random Effects Model
Adverse Cardiovascular
Event(s) Model Odds Ratio p Value
Cardiac death Fixed 2.92 (1.01–8.42) 0.047
Random 3.28 (0.79–13.71) 0.104
SCD/aborted SCD Fixed 2.39 (0.87–6.58) 0.091
Random 2.40 (0.87–6.60) 0.091
SCD Fixed 1.45 (0.47–4.52) 0.519
Random 1.51 (0.43–5.32) 0.525
HF death Fixed 5.68 (1.04–31.07) 0.045
Random 5.68 (1.04–31.07) 0.045
All cause mortality Fixed 4.46 (1.53–13.01) 0.006
Random 4.46 (1.53–13.01) 0.006
Values are odds ratio (95% conﬁdence interval).
HF  heart failure; SCD  sudden cardiac death.ssociated with ICD placement and recognize the effects of both
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Letters to the Editor 763appropriate versus inappropriate ICD shocks. Further improve-
ment in the precision in selecting just which patients will stand
to benefit from ICD therapy (and those who will not) will allow
for cost containment of a potentially life-saving, albeit costly,
intervention. The second scenario will require careful investiga-
tion in an adequately powered prospective manner as proposed in
our paper.
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Consideration of Patient Safety
Using Real-Time 3D TEE During
LA Pulmonary Vein Ablation
In a recent issue of iJACC, Faletra et al. (1) reported real-time
RT) 3-dimensional (3D) transesophageal echocardiography
TEE) imaging of the left atrium (LA) and pulmonary veins
PVs) and described examples of its use during catheter-based
V ablation. RT 3D TEE may offer a useful tool to enhance our
nderstanding and evaluation of cardiac structures during per-
utaneous treatment procedures. However, we disagree with
aletra et al. (1) to forecast that RT 3D TEE may become a
seful complementary imaging modality in anatomy-driven ra-
iofrequency (RF) PV isolation. We consider that patient safety
s a serious concern with using RT 3D TEE during RF LA
osterior wall (PW) and PV ablation.
The esophagus is immediately contiguous to the LAPW (Fig.
). Esophageal injury has been reported with delivery of RF
esions at the LAPW contiguous to the esophagus during LA
ntraoperative or percutaneous transcatheter ablation for atrial
brillation (2,3). Placement of the TEE probe in the esophagus
ushes the anterior wall into the LAPW and increases both theontiguous area and the proximity, particularly in a dilated LA.
his could certainly increase the risk of esophageal injury during
APW ablation, such as atrioesophageal fistula/perforation.
ecause of the high mortality of this complication, avoiding and
reventing esophageal injury is paramount during LA ablation
rocedures. In addition, the TEE transducer, when manipulated
n the posteriorly limited esophageal space with its narrowing
ltrasonic beam, is too close to visualize the entire LA roof and
he posteriorly located and oriented right and left inferior veins.
inally, TEE requires an expert echocardiographer, is poorly
olerated by patients with prolonged placement, and requires
eavy sedation and/or general anesthesia. These disadvantages
ave limited its routine use, especially during LA and PV
blation procedures.
In our laboratory, in addition to fluoroscopy, a 3D electroanat-
mic mapping system with real-time intracardiac echocardio-
raphic imaging is the perfect combined technique for routine
onitoring and guidance of LA and PV ablation for atrial fibril-
ation.
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Figure 1. Intracardiac Echocardiographic Image Showing the LA
Posterior Wall Contiguous to the Esophagus
Intracardiac echocardiographic image with the transducer placed in the
right atrium (RA) showing the left atrial (LA) posterior wall immediately con-
tiguous to the esophagus (E) (horizontal arrows) anterior wall (downward
arrows), and projected ostial location of the left pulmonary veins (LPVs) and
lower right pulmonary vein (LRPV).456–62.
